Sumitomo Pharma America, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$107.9M
Doctors Paid
48,574
Transactions
238,455
2024 Total
$47.7M
Payment Breakdown by Category
Research$98.6M (91.4%)
Food & Beverage$4.3M (4.0%)
Consulting$1.7M (1.6%)
Travel$452,183 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $98.6M | 22,531 | 91.4% |
| Food and Beverage | $4.3M | 211,506 | 4.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 1,550 | 2.2% |
| Consulting Fee | $1.7M | 530 | 1.6% |
| Travel and Lodging | $452,183 | 1,282 | 0.4% |
| Grant | $265,976 | 44 | 0.2% |
| Charitable Contribution | $217,345 | 15 | 0.2% |
| Education | $11,861 | 989 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $3,000 | 1 | 0.0% |
| Gift | $2,665 | 1 | 0.0% |
| Entertainment | $1,227 | 6 | 0.0% |
Payments by Type
Research
$98.6M
22,531 transactions
General
$9.3M
215,924 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized Double-blind Parallel-group Placebocontrolled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia | $8.0M | 0 | 432 |
| A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY | $7.0M | 1 | 1,870 |
| A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS | $5.7M | 7 | 1,433 |
| SERENE | $5.6M | 2 | 1,623 |
| A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | $5.1M | 0 | 860 |
| RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | $4.6M | 0 | 808 |
| A Randomized Double-blind Parallel-group Placebo-controlled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia | $4.5M | 0 | 413 |
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects with Schizophrenia | $4.5M | 0 | 132 |
| A Randomized Open-Label Single Dose Cross-over Study of Gastric Emptying Rate: SEP-363856 vs Prior Antipsychotic Standard of Care in Subjects with Schizophrenia | $3.4M | 0 | 137 |
| An Open-Label Fixed Sequence Multiple Dose Study of Glucose and Insulin Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects with Schizophrenia Suffering from Metabolic Dysregulation | $3.1M | 0 | 102 |
| A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder | $3.0M | 0 | 552 |
| A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication | $2.9M | 0 | 1,603 |
| A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | $2.8M | 1 | 1,198 |
| A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. | $2.7M | 0 | 1,448 |
| A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | $2.5M | 0 | 209 |
| A Double-Blind Randomized Multiple Dose Study of Weight Associated Parameters: SEP?363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects with Schizophrenia Suffering from Metabolic Dysregulation | $2.4M | 0 | 148 |
| A Double-Blind Placebo-Controlled Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects with Schizophrenia | $2.2M | 0 | 680 |
| A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy | $2.1M | 3 | 760 |
| A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension | $1.9M | 1 | 140 |
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $1.7M | 0 | 211 |
| A TWO-PART, OPEN-LABEL, FIXED-SEQUENCE, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE EFFECTS OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF RELUGOLIX, ESTRADIOL AND NORETHINDRONE AFTER ADMINISTRATION OF THE RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE FIXED-DOSE COMBINATION TABLET IN HEALTHY POSTMENOPAUSAL WOMEN OR OF RELUGOLIX AFTER ADMINISTRATION OF A SINGLE 120-MG DOSE IN HEALTHY ADULT MEN | $1.5M | 0 | 7 |
| A Double-Blind, Randomized, Multiple Dose Study of Weight Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation | $1.3M | 0 | 47 |
| An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia | $1.3M | 0 | 341 |
| A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia | $1.3M | 0 | 116 |
| A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF VIBEGRON IN MEN WITH OVERACTIVE BLADDER (OAB) SYMPTOMS ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH) | $1.1M | 0 | 91 |
| A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of OralTP1454 | $1.1M | 0 | 104 |
| An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication | $1.1M | 0 | 51 |
| SPIRIT EXTENSION AN INTERNATIONAL PHASE 3 OPENLABEL, SINGLEARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX COADMINISTERED WITH LOWDOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSISASSOCIATED PAIN | $1.0M | 0 | 3 |
| A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication | $996,595 | 0 | 383 |
| A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis | $921,030 | 0 | 177 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Donald Garcia, Md, MD | Psychiatry | Austin, TX | $539,515 | $0 |
| John Sleasman, Md, MD | Pediatrics | Durham, NC | $275,437 | $0 |
| Edwin Parsley, D.o, D.O | Critical Care Medicine | Houston, TX | $166,067 | $0 |
| Dr. Matt Rosenberg, M.d, M.D | Family Medicine | Jackson, MI | $165,250 | $0 |
| Jeffrey Frankel, Md, MD | Specialist | Burien, WA | $159,205 | $0 |
| David Staskin, Md, MD | Urology | Brighton, MA | $132,355 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $119,915 | $0 |
| Dr. Ashley Tapscott, D.o, D.O | Urology | Nashville, TN | $101,911 | $0 |
| Sean Collins | Radiation Oncology | Washington, DC | $86,561 | $0 |
| Michael Kennelly, Md, MD | Urogynecology and Reconstructive Pelvic Surgery | Charlotte, NC | $79,369 | $0 |
| Eleni Efstathiou, M.d, M.D | Medical Oncology | Houston, TX | $76,851 | $0 |
| Scott Macdiarmid, Md, MD | Urology | Greensboro, NC | $76,091 | $0 |
| Dr. Nathaniel Barnes, M.d, M.D | Urology | Webster, TX | $72,323 | $0 |
| Vahan Kassabian, M.d, M.D | Urology | Roswell, GA | $70,567 | $0 |
| Diane Newman, Crnp, CRNP | Adult Health | Philadelphia, PA | $64,230 | $0 |
| Marc Pliskin, Do, DO | Urology | Cincinnati, OH | $64,138 | $0 |
| Dr. Damian Sorce, Md, MD | Urology | Parker, CO | $62,224 | $0 |
| Gordon Brown, Do, DO | Urology | Cherry Hill, NJ | $59,239 | $0 |
| Lawrence Gervasi, Md, MD | Urology | Middleburg Heights, OH | $50,399 | $0 |
| Dr. Benjamin Brucker, Md, MD | Urology | New York, NY | $47,329 | $0 |
| Dr. Scott Sellinger, Md, MD | Urology | Tallahassee, FL | $45,121 | $0 |
| Dr. Elliot Cazes, M.d, M.D | Specialist | Tampa, FL | $45,049 | $0 |
| Jay Cohen, Md, MD | Obstetrics & Gynecology | Plantation, FL | $43,867 | $0 |
| Dr. Billy Catherino, M.d., Ph.d, M.D., PH.D | Reproductive Endocrinology | Bethesda, MD | $42,302 | $0 |
| Dr. Daniel Von Hoff, M.d, M.D | Hematology & Oncology | Scottsdale, AZ | $40,720 | $0 |
About Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. has made $107.9M in payments to 48,574 healthcare providers, recorded across 238,455 transactions in the CMS Open Payments database. In 2024, the company paid $47.7M. The top product by payment volume is MYFEMBREE ($22.8M).
Payments were distributed across 241 medical specialties. The top specialty by payment amount is Urology ($2.3M to 4,327 doctors).
Payment categories include: Food & Beverage ($4.3M), Consulting ($1.7M), Research ($98.6M), Travel & Lodging ($452,183).
Sumitomo Pharma America, Inc. is associated with 3 products in the CMS Open Payments database.